According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- new Authorized Treatment Centers (“ATCs”) were experiencing longer timelines to begin treating patients with Amtagvi;
- Iovance’s sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs;
- the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product; and
- as a result of the foregoing, defendants’ positive statements about Iovance’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
